Type 2 Diabetes Therapy

Advances made in small molecule inhibitors of PTP1B for treating type 2 diabetes

Published in Obesity and Diabetes Week, April 21st, 2003

Recent advances have been made in the development of small molecule inhibitors of protein tyrosine phosphatase 1B (PTP1B) for the treatment of patients with insulin resistance and type 2 diabetes.

"Protein tyrosine phosphatases (PTPs) are a large family of diverse molecules that play an important role in both activating and attenuating a wide variety of cellular responses. One of these phosphatases, PTP1B, is clearly involved in attenuating insulin signaling, and much effort has been devoted towards the development of inhibitors of this enzyme as a therapeutic approach to treat insulin resistance and type 2 diabetes," scientists in the United States report.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2003-04-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry